Resources

Featured

2024 Antibody Engineering & Therapeutics

We are excited to share the latest data on screening checkpoint inhibitors (anti-PD1, anti-CTLA4), and a T cell engager (anti-CD3, anti-EpCAM), revealing their mechanism of action in the Cypre tumor microenvironment organoids and the data's implications for cytokine release syndrome.

2024 AACR Poster

Cypre is proud to present our poster with our partners at CRL titled “Automated 42 PDX 3D in vitro tumor models of the TME screen immuno-oncology and targeted compounds and biologics for antitumor effects and MOA” on Tuesday, April 9th at 9am-noon in Section 28 (Poster 23, Abstract 4703). The Poster will be available after the conference.

Research Publication

We published a peer-reviewed research paper with our collaborators at Cedars Sinai Medical Center and Stanford, called “A Simple Three-dimensional Hydrogel Platform Enables Ex Vivo Cell Culture of Patient and PDX Tumors for Assaying Their Response to Clinically Relevant Therapies”, highlighting the utility of our technology in screening patient-derived tumors against small molecules.

2023 CELLS Publication

April 13, 2023: Cypre and Charles River publish a peer-reviewed manuscript detailing the Cypre 3D tumor platform, titled "A Novel Hydrogel-Based 3D In Vitro Tumor Panel of 30 PDX Models Incorporates Tumor, Stromal and Immune Cell Compartments of the TME for the Screening of Oncology and Immuno-Therapies"

2022 SITC Posters

Cypre presents posters at the Society for Immunotherapy Conference (SITC) titled “#299 3D in vitro Tumor microenvironment models for screening CAR-T cell therapy efficacy.” , “#1447 A 30 PDX Panel of 3D in vitro tumor models identifies responders”

2022 AACR Poster

Cypre presented a joint poster with Charles River at AACR titled “#1880 - High throughput screening of 30 PDX cell lines in a 3D ECM hydrogel platform, incorporating tumor, stroma and immune components to demonstrate simultaneous investigation of multiple anti-tumor modalities”, highlighting the 3D Tumor Model Platform in screening 30 PDX models simulatenously with both small molecules and antibodies.

Webinar

Cypre co-presented an invited Endpoints webinar with Charles River titled “Change the Game: An Examination of Cutting-Edge Novel Oncology Screening Tools.” The webinar is now available on-demand through the link below.

Drug Discovery Today

Cypre presents a joint publication with Charles River titled “How to build a tumor: An industry perspective”

2021 AACR Poster

Cypre presented a joint poster with Charles River at AACR titled “3184 - 3D in vitro tumor model platform for screening patient-derived NSCLC, CRC, and RCC tumors with targeted therapy and immunotherapy”, highlighting the 3D Tumor Model Platform in screening PDX models with both small molecules and antibodies.

Webinar – Charles River

Cypre co-presented a webinar with Charles River titled “Predict Anticancer Efficacy with a New In Vitro 3D Modeling Platform”. The webinar is now available on-demand through the link below.

2019 AACR Presentation

We presented a minisymposium talk alongside our collaborators at Genentech called “An in vitro 3D immune exclusion tumor model engineered in a layer-by-layer fashion”, highlighting our platform’s application in creating the immune excluded phenotype with mouse cells and assaying T cell infiltration through our ECM hydrogel, VersaGel®, and subsequent T cell-mediated killing.

Technical Data Sheet

This joint technical data sheet with Charles River describes the Cypre 3D Tumor Model Platform for targeted and immunotherapy screening.

2023 AACR Poster

Cypre presents a poster in collaboration with Charles River at the American Association for Cancer Research (AACR) conference titled “#1722 - KRAS, BRAF, BRCA1 and EGFR Mutation-Specific Panels Using Hydrogel-Based 3D In Vitro Tumor Models"